Very inspiring talk about non-mendelian genetics to close the II Bootcamp! Thanks Roddy Walsh 🇪🇺 🇺🇦 for your visit to Hospital Universitari Bellvitge | HUB Universitat de Barcelona

Felices de comprobar que la #genética cardiovascular atrae un interés creciente entre las nuevas -y las asentadas- generaciones de #cardiólogos 🧬🚀 Este fin de semana hemos compartido con el Hospital Universitari Bellvitge | HUB, nuestra misión por transmitir el conocimiento que hemos consolidado en el

CardioGenomics 2024, the meeting of the ESC Council on Cardiovascular Genomics. See you there! European Society of Cardiology Antoine Bondue . esc365.escardio.org/event/1652

RWE and 36-Week Outcomes of Patients With OCHM Treated W/ Mavacamten 🔄Rapid and sustained improvements in LVOT gradients were observed throughout the 36-week 📉Mean LVEF remained stable overall, w/ temporary declines in some patients resolving after mava discontinuation

Fascinating case report of Brugada syndrome unmasked in a young Indonesian female undergoing lacosamide epilepsy treatment, and found to carry the SCN5A:p.R965C variant. A brief🧵on what is probably the most prevalent rare(ish) Brugada genetic variant: frontiersin.org/articles/10.33…

🚨🚨🚨 MAJOR news in the #amyloidosis world this morning with positive topline results of #HELIOS-B. #Vutrisiran met all primary & secondary endpoints. Let's break down what we know... #StanfordAmyloidCenter (1/13)

.@lorenzoest7: "El uso del NT-proBNP y la intensificación del tto. diurético podrían tener un papel como marcadores de progresión en pacientes con amiloidosis cardiaca por ATTR, según este estudio que incluye más de 2.000 pacientes". #BlogSEC JóvenesSEC ow.ly/tZpl50SwWAA

Five years ago I saw a 46 year-old 👧 at clinic who had a pacemaker (PM) implanted aged 43 due to complete AVB. No other 🫀 findings but her father and grand-father also received a PM at young age 🧐 (1/16)

Arrhythmogenic Cardiomyopathy Risk 🧬 #Genetics #HeartHealth #Research New study introduces a tool to assess arrhythmic risk in DSP gene variant carriers EHJ Editor-in-Chief academic.oup.com/eurheartj/adva…

🏥 Luz verde al CAR-T ARI0002h desarrollado por el #CLÍNIC-IDIBAPS para pacientes con #mielomamúltiple en recaída. ✅ El Comité de AEMPS ha dado el visto bueno para aprobarlo como medicamento de terapia avanzada de fabricación no industrial. 👉 clinicbarcelona.org/noticias/luz-v…

¿Te han aceptado una comunicación en #SEC24? ¿Quieres convertirla en un artículo científico? ¡Enhorabuena! Vuelve la #PubliBeca, tu oportunidad de recibir el asesoramiento para transfórmala en publicación. ¡No dejes pasar esta oportunidad! 🚀secardiologia.es/institucional/… JóvenesSEC

Pleased to share our work “Prognostic Role of Tissue Iron Deficiency Measured by sTfR Levels in Heart Failure Patients without Systemic Iron Deficiency or Anemia”mdpi.com/2910124 #mdpijcm a través de MDPI IDIBELL Hospital Universitari Bellvitge | HUB

Not many days we have a new drug reducing mortality in CV disease Congratulations to the HELIOS-B investigators! #ESCCongress2024

⭐⭐ Rising stars from Hospital Universitari Bellvitge | HUB presenting at #ESCCongress2024 @lorenzoest7 Albert Cabarrocas ResiSEC JóvenesSEC

Help!!! I need to prepare a session for my hospital about the highlights of #ESCCongress2024 What have been IYO the most relevant trials about HF & Cardiomyopathies? JóvenesSEC

A milestone in #transthyretin #amyloidosis ACT-EARLY kicks off - acoramidis vs placebo for the prevention of #ATTR phenotype in patients at risk. clinicaltrials.gov/study/NCT06563… investor.bridgebio.com/static-files/6… #CardioTwitter

El 7/10 farem la primera sessió d'actualització en cardiologia del curs. Parlarem de les primeres guies sobre miocardiopaties amb professionals de diferents centres hospitalaris de Catalunya. 🔴Presencial a la seu de l'acadèmia 🔴Per streaming Programa: i.mtr.cool/pavorpyjlu

Share your scientific expertise in the field of cardiovascular genomic medicine. The deadline to submit your abstract has been extended to 11 September. Submit today and register to join us in Antwerp on 6-7 December! bit.ly/4d8lyDw #CVD #CardioGenomics

📢About 18% of #HFpEF or #HFmrEF patients are diagnosed with #ATTR-CM 🫀‼️ ⚠️International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with HFpEF or HFmrEF 🔝Recently published in Amyloid🫀‼️

PhD at last!! I am very grateful to my supervisors Pablo Garcia-Pavia & Fernando Domínguez and to all the ICC Unit of Cardiología Puerta de Hierro🫀 Thanks to all the thesis committee for their reviews and suggestions too.